| Theme | New frontiers of calcimimetics | |
|---|---|---|
| Title | Etelcalcetide | |
| Publish Date | 2018/09 | |
| Author | Masaki Oya | Department of Nephrology, Wakayama Medical University |
| Author | Takashi Shigematsu | Department of Nephrology, Wakayama Medical University |
| [ Summary ] | Etelcalcetide is the second calcimimetic agent to be approved in Japan. It is the first intravenous calcimimetic agent in the world. It is designed to be administered through dialysis circuits. This type of administration is expected to reduce the burden of medication administration on patients. Etelcalcetide strongly suppresses serum intact PTH levels and decreases serum calcium, phosphate and intact FGF23 levels. Etelcalcetide is expected to exhibit its effects through administion as an intravenous injection agent. | |